# **I** Interventions targeting nonsymptomatic cases can be important to

- 2 prevent local outbreaks: SARS-CoV-2 as a case-study
- 3
- 4 Authors
- 5 Francesca A. Lovell-Read<sup>1\*</sup>, Sebastian Funk<sup>2</sup>, Uri Obolski<sup>3,4</sup>, Christl A. Donnelly<sup>5,6</sup>, Robin N.
- 6 Thompson<sup>1,2,7,8</sup>
- 7

## 8 Affiliations

- <sup>9</sup> <sup>1</sup>Mathematical Institute, University of Oxford, Oxford, UK
- <sup>10</sup> <sup>2</sup>Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene &
- 11 Tropical Medicine, London, UK
- <sup>12</sup> <sup>3</sup>Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel
- <sup>4</sup>School of Public Health, Tel Aviv University, Tel Aviv, Israel
- <sup>5</sup>Department of Statistics, University of Oxford, Oxford, UK
- 15 <sup>6</sup>MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease
- 16 Epidemiology, Imperial College London, London, UK
- 17 <sup>7</sup>Mathematics Institute, University of Warwick, Coventry, UK
- 18 <sup>8</sup>The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research,
- 19 University of Warwick, Coventry, UK
- 20
- 21 \* Corresponding author
- 22 Address: Merton College, Merton Street, Oxford, OX1 4JD
- 23 E-mail: <u>francesca.lovell-read@merton.ox.ac.uk</u>. Tel: +44 (0)7511 676 592.

24

### 25 Abstract

26 During infectious disease epidemics, an important question is whether cases travelling to new 27 locations will trigger local outbreaks. The risk of this occurring depends on the transmissibility of 28 the pathogen, the susceptibility of the host population and, crucially, the effectiveness of 29 surveillance in detecting cases and preventing onward spread. For many pathogens, transmission 30 from presymptomatic and/or asymptomatic (together referred to as nonsymptomatic) infectious 31 hosts can occur, making effective surveillance challenging. Here, using SARS-CoV-2 as a case-32 study, we show how the risk of local outbreaks can be assessed when nonsymptomatic 33 transmission can occur. We construct a branching process model that includes nonsymptomatic 34 transmission, and explore the effects of interventions targeting nonsymptomatic or symptomatic 35 hosts when surveillance resources are limited. We consider whether the greatest reductions in local 36 outbreak risks are achieved by increasing surveillance and control targeting nonsymptomatic or 37 symptomatic cases, or a combination of both. We find that seeking to increase surveillance of 38 symptomatic hosts alone is typically not the optimal strategy for reducing outbreak risks. Adopting 39 a strategy that combines an enhancement of surveillance of symptomatic cases with efforts to find 40 and isolate nonsymptomatic infected hosts leads to the largest reduction in the probability that 41 imported cases will initiate a local outbreak.

42

## 43 Keywords

44 mathematical modelling; infectious disease epidemiology; SARS-CoV-2; COVID-19;

45 presymptomatic infection; asymptomatic infection; disease surveillance

46

## 47 **1. Introduction**

48	Emerging epidemics represent a substantial challenge to human health worldwide [1-4]. When
49	cases are clustered in specific locations, two key questions are: i) Will exported cases lead to local
50	outbreaks in new locations? and ii) Which surveillance and control strategies in those new
51	locations will reduce the risk of local outbreaks?
52	
53	Branching process models are used for a range of diseases to assess whether cases that are newly
54	arrived in a host population will generate a local outbreak driven by sustained local transmission
55	[5-11]. These models can also be used to predict the effectiveness of potential control
56	interventions. For example, early in the COVID-19 pandemic, Hellewell et al. [12] used
57	simulations of a branching process model to predict whether or not new outbreaks would fade out
58	under different contact tracing strategies. Thompson [13] estimated the probability of local
59	outbreaks analytically using a branching process model and found that effective isolation of
60	infectious hosts leads to a substantial reduction in the outbreak risk.
61	
62	A factor that can hinder control interventions during any epidemic is the potential for individuals
63	to transmit a pathogen while not showing symptoms. For COVID-19, the incubation period has
64	been estimated to last approximately five or six days on average [14, 15], and presymptomatic
65	transmission can occur during that period [16-20]. Additionally, asymptomatic infected individuals
66	(those who never develop symptoms) are also thought to contribute to transmission [16, 21, 22].
67	
68	Motivated by the need to assess the risk of outbreaks outside China early in the COVID-19
69	pandemic, we show how the risk that imported cases will lead to local outbreaks can be estimated
70	using a branching process model. Unlike standard approaches for estimating the probability of a

72	explicitly. Using a function that characterises the efficacy of interventions for different
73	surveillance efforts (denoted $f(\rho, \delta)$ in the model), we explore the effects of interventions that aim
74	to reduce this risk. Under the assumption that detected infected hosts are isolated effectively, we
75	consider whether it is most effective to dedicate resources to enhancing surveillance targeting
76	symptomatic individuals, to instead focus on increasing surveillance for nonsymptomatic
77	individuals, or to use a combination of these approaches.
78	
79	We show that, when surveillance resources are limited, the maximum reduction in the outbreak
80	risk almost always corresponds to a mixed strategy involving enhanced surveillance of both
81	symptomatic and nonsymptomatic hosts. This remains the case even if the surveillance effort
82	required to find nonsymptomatic infected individuals is significantly larger than the effort required
83	to find symptomatic individuals. This highlights the benefits of not only seeking to find and isolate
84	symptomatic hosts, but also dedicating resources to detecting nonsymptomatic cases during
85	infectious disease epidemics.
86	
87	2. Methods
88	2.1 Model

89 We consider a branching process model in which infectious individuals are classified as 90 asymptomatic ( $I_1$ ) or symptomatic ( $I_2$ ). Hosts in any of these classes may

91 generate new infections. The parameter  $\xi$  represents the proportion of new infections that are

92 asymptomatic, so that a new infection either involves increasing A by one (with probability  $\xi$ ) or

93 increasing  $I_1$  by one (with probability  $1 - \xi$ ).

medRxiv preprint doi: https://doi.org/10.1101/2020.11.06.20226969; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Presymptomatic hosts may go on to develop symptoms (transition from  $I_1$  to  $I_2$ ) or be detected and isolated (so that  $I_1$  decreases by one). Symptomatic individuals ( $I_2$ ) can be isolated (so that  $I_2$ decreases by one) or be removed due to recovery or death (so that again  $I_2$  decreases by one). Similarly, asymptomatic hosts may be detected and isolated, or recover (so that *A* decreases by one in either case).

100

A schematic showing the different possible events in the model is shown in Fig 1A. The analogous
 compartmental differential equation model to the branching process model that we consider is
 given by

104 
$$\frac{\mathrm{d}A}{\mathrm{d}t} = \xi(\eta\beta A + \alpha\beta I_1 + \beta I_2) - \frac{\varepsilon\gamma}{1 - \mathrm{f}(\rho_1, \delta)}A - \nu A_1$$

105 
$$\frac{\mathrm{d}I_1}{\mathrm{d}t} = (1-\xi)(\eta\beta A + \alpha\beta I_1 + \beta I_2) - \frac{\varepsilon\gamma}{1-\mathrm{f}(\rho_1,\delta)}I_1 - \lambda I_1,$$

106 
$$\frac{\mathrm{d}I_2}{\mathrm{d}t} = \lambda I_1 - \frac{\gamma}{1 - \mathrm{f}(\rho_2, \delta)} I_2 - \mu I_2$$

107 The parameters of the model, and the form of the function  $f(\rho, \delta)$  that describes how the expected 108 time to isolation is reduced for a given surveillance effort, are outlined below.

109



111	Fig 1. The branching process model used in our analyses. A. Schematic showing the different event
112	types in the branching process model. The parameters of the model are described in the text and in Table
113	1. B. The relationship between the surveillance intensification effort ( $\rho$ ) and the proportional reduction in
114	the expected time to isolation ( $f(\rho, \delta)$ ), shown for different values of the parameter $\delta$ (solid lines). The
115	parameter $\delta \in (0,1)$ represents the upper bound of $f(\rho, \delta)$ (dotted lines). This general functional
116	relationship between surveillance effort and isolation effectiveness is assumed to hold for surveillance of
117	both nonsymptomatic and symptomatic individuals, although nonsymptomatic hosts are more challenging
118	to detect than symptomatic hosts ( $\varepsilon < 1$ ).
119	
120	In our model, the parameter $\beta$ and its scaled counterparts $\alpha\beta$ and $\eta\beta$ represent the rates at which
121	symptomatic, presymptomatic and asymptomatic hosts generate new infections, respectively.

122 Since we are modelling the beginning of a potential local outbreak, we assume that the size of the

susceptible population remains approximately constant and do not track the depletion of this

124 population. The parameter  $\lambda$  governs the rate at which presymptomatic individuals develop

125 symptoms, so that the expected duration of the presymptomatic period is  $1/\lambda$  days in the absence

126 of interventions. Similarly, without interventions, the expected durations of the symptomatic and

127 asymptomatic infectious periods are  $1/\mu$  days and  $1/\nu$  days, respectively.

128

129 The baseline rate at which symptomatic individuals are detected and isolated is determined by the 130 parameter  $\gamma$ . Assuming that nonsymptomatic individuals are more difficult to detect than 131 symptomatic individuals, we take the analogous quantity for nonsymptomatic hosts to be  $\varepsilon\gamma$ , 132 where the scaling factor  $\varepsilon < 1$  reflects the fact that interventions targeting nonsymptomatic hosts 133 are likely to be less effective for the same surveillance effort. We assume that the sensitivity of 134 surveillance is identical for presymptomatic and asymptomatic individuals, and therefore use the 135 same isolation rate for both of these groups.

136

The parameters  $\rho_1$  and  $\rho_2$  represent the surveillance intensification effort targeted at 137 nonsymptomatic and symptomatic hosts, respectively. The function  $f(\rho, \delta) = \frac{\delta \rho}{1+\rho}$  governs the 138 139 proportional reduction in the expected time to isolation for a given surveillance effort,  $\rho$  (for a 140 similar approach in which the proportion of infectious cases prevented is assumed to be a function 141 of control effort, see Matthews *et al.* [27]). The functional form of  $f(\rho, \delta)$  is chosen for three main 142 reasons. First, it generates a reduced expected time to isolation when the surveillance effort 143 increases. Second, since the proportional reduction in the expected time to isolation is bounded 144 above by the parameter  $\delta \in (0,1)$ , the isolation rate saturates and cannot increase indefinitely. Third, the gradient  $\frac{\partial f}{\partial \rho}$  decreases with the surveillance effort  $\rho$ , meaning that an increase in the 145 146 surveillance effort has a greater impact at low surveillance efforts compared to when this effort is 147 already large [27]. The function  $f(\rho, \delta)$  is shown in Fig 1B for different values of the parameter  $\delta$ . 148

#### 149 **2.2 Reproduction number**

150 The basic reproduction number,  $R_0$ , represents the expected number of secondary infections 151 generated by a single infected individual introduced at the start of their infection into a fully 152 susceptible population in the absence of intensified surveillance:

153 
$$R_0 = \frac{\xi \eta \beta}{\nu + \epsilon \gamma} + (1 - \xi) \left[ \frac{\alpha \beta}{\lambda + \epsilon \gamma} + \frac{\lambda}{\lambda + \epsilon \gamma} \frac{\beta}{\gamma + \mu} \right].$$

154 This expression is the sum of the expected number of transmissions from a host who begins in the 155 asymptomatic class and from a host who begins in the presymptomatic infectious class, weighted 156 by the respective probabilities  $\xi$  and  $1 - \xi$  that determine the chance that the host experiences a 157 fully asymptomatic course of infection. The expected number of transmissions from a host who 158 begins in the presymptomatic infectious class comprises transmissions occurring during the

- 159 incubation period and transmissions occurring during the symptomatic period, accounting for the
- 160 possibility that the host is isolated prior to developing symptoms.

161

162 The proportion of infections arising from presymptomatic hosts in the absence of intensified

163 surveillance is then given by

164 
$$K_{p} = \frac{\frac{(1-\xi)\alpha}{\lambda+\epsilon\gamma}}{\frac{\xi\eta}{\nu+\epsilon\gamma} + (1-\xi)\left[\frac{\alpha}{\lambda+\epsilon\gamma} + \frac{\lambda}{\lambda+\epsilon\gamma}\frac{1}{\gamma+\mu}\right]}, \quad (1)$$

and the equivalent quantity for asymptomatic hosts is given by

166 
$$K_{a} = \frac{\frac{\xi\eta}{\nu + \epsilon\gamma}}{\frac{\xi\eta}{\nu + \epsilon\gamma} + (1 - \xi) \left[\frac{\alpha}{\lambda + \epsilon\gamma} + \frac{\lambda}{\lambda + \epsilon\gamma} \frac{1}{\gamma + \mu}\right]}.$$
 (2)

167

### 168 **2.3 Baseline values of model parameters**

Since this research was motivated by the need to estimate outbreak risks outside China in the initial stages of the COVID-19 pandemic, we used a baseline set of parameter values in our analyses that was informed by studies conducted during this pandemic (Table 1). Where possible, these parameter values were obtained from existing literature. However, we also performed sensitivity analyses to determine how our results varied when the parameter values were changed (see Supplementary Text S3 and Supplementary Figs S3-12). In Table 1, and throughout, rounded values are given to three significant figures.

177 Table 1. Parameters of the model and the values used in the baseline version of our analysis.

Parameter	Meaning	<b>Baseline value</b>	Justification
D	Expected number of secondary	$R_0 = 3$	Within estimated range for SARS-CoV-2
Λ <sub>0</sub>	infections caused by a single		[28-31]

	infected individual (when $\rho_1 =$		
	$\rho_2 = 0)$		
ξ	Proportion of infections that are asymptomatic	$\xi = 0.2$	[32-34]
β	Rate at which symptomatic individuals generate new infections	$\beta = 0.336$ $days^{-1}$	Chosen so that $R_0 = 3$
α	Relative infectiousness of presymptomatic individuals compared to symptomatic individuals	$\alpha = 2.78$	Chosen so that 48.9% of transmissions arise from presymptomatic hosts (i.e. $K_p = 0.489$ ) [16]
η	Relative infectiousness of asymptomatic individuals compared to symptomatic individuals	$\eta = 0.519$	Chosen so that 10.6% of transmissions arise from asymptomatic hosts (i.e. $K_a = 0.106$ ) [16]
γ	Isolation rate of symptomatic individuals without intensified surveillance	$\gamma = 0.0924$ $days^{-1}$	Chosen so that $\frac{1}{\gamma + \mu} = 4.6$ days [35]
ε	Relative isolation rate of nonsymptomatic individuals without intensified surveillance (compared to symptomatic individuals)	$\varepsilon = 0.1$	Assumed; chosen within the range $\varepsilon \in (0,1)$ (for different values, see Fig S7)
λ	Rate at which presymptomatic individuals develop symptoms	$\lambda = 0.5 \text{ days}^{-1}$	[20]
μ	Recovery rate of symptomatic individuals	$\mu = 1/8  \mathrm{days}^{-1}$	[36-38]
ν	Recovery rate of asymptomatic individuals	$\nu = 0.1 \text{ days}^{-1}$	Chosen so that, in the absence of interventions, the expected duration of infection is identical for all infected hosts $\left(\frac{1}{\nu} = \frac{1}{\lambda} + \frac{1}{\mu}\right)$
δ	Upper bound on the fractional reduction in the time to isolation	$\delta = 0.8$	Assumed; chosen within the natural range $\delta \in (0,1)$ (for different values, see Fig S11)
$ ho_1$	Surveillance intensification effort targeted at nonsymptomatic hosts	$ \rho_1 $ allowed to vary in the range [0,20]	N/A – range of values explored
$ ho_2$	Surveillance intensification effort targeted at symptomatic hosts	$ \rho_2 $ allowed to vary in the range [0,20]	N/A – range of values explored

178

179 The value of the parameter governing the baseline rate at which symptomatic individuals are

180 isolated,  $\gamma$ , was chosen to match empirical observations which indicate that individuals who seek

181 medical care prior to recovery or death do so around four to six days after symptom onset [35]. 182 Specifically, we assumed that the period of time to the first medical visit could be used a proxy for 183 the time to isolation, and chose  $\gamma$  so that the expected time period to isolation conditional on 184 isolation occurring during the symptomatic period was given by  $\frac{1}{\gamma + \mu} = 4.6$  days [35]. This is 185 different to the time period that we refer to as the expected time to isolation for symptomatic hosts, 186 which is  $\frac{1}{\gamma}$  days (see Methods).

187

188 **2.4 Probability of a local outbreak** 

189 For stochastic simulations of compartmental epidemiological models starting from a small number 190 of hosts infected initially, there are generally two qualitatively different types of behaviour. The 191 pathogen may fade out rapidly, or case numbers may begin to increase exponentially (only starting 192 to fade out once the number of susceptible individuals has been sufficiently depleted, unless public 193 health measures are introduced to reduce transmission). Consequently, running many simulations 194 of those types of model with  $R_0$  larger than but not close to one, the epidemic size is distributed 195 bimodally, with the total number of individuals ever infected falling into one of two distinct ranges 196 (for a simple example, see Supplementary Fig S1A; see also [39-41]). In that scenario, a natural 197 definition for the probability of a local outbreak is therefore the proportion of outbreak simulations 198 for which the total number of infected individuals falls into the higher of these two ranges.

199

Here, since we are considering the initial phase of potential local outbreaks, we instead considered a branching process model in which depletion of susceptibles was not accounted for. If simulations of branching process models are run, then in each simulation the pathogen either fades out with few infections or case numbers generally increase indefinitely. The probability of a local outbreak

starting from a small number of infected hosts then corresponds to the proportion of simulations in which the pathogen does not fade out quickly and case numbers increase indefinitely instead. This again provides a natural definition of a local outbreak, since simulations can be partitioned into two distinct sets (for an example in which simulations of a simple branching process model are used to calculate the probability of a local outbreak, see Supplementary Fig S1B).

209

As an alternative to repeated simulation, we instead use our branching process model (Fig 1A) to

211 perform analytic calculations of the probability that a single imported infectious host initiates a

212 local outbreak. To do this, we denote the probability of a local outbreak not occurring, starting

213 from *i* presymptomatic hosts, *j* symptomatic hosts, and *k* asymptomatic hosts, by  $q_{i,j,k}$ . Starting

from one presymptomatic host (so that i = 1 and j = k = 0), there are four possibilities for the

215 next event. That host could:

216 i) generate a new asymptomatic infection (with probability 
$$\frac{\xi \alpha \beta}{\alpha \beta + \lambda + \frac{\epsilon \gamma}{1 - f(\rho_1, \delta)}}$$
);

217 ii) generate a new presymptomatic infection (with probability  $\frac{(1-\xi)\alpha\beta}{\alpha\beta+\lambda+\frac{\varepsilon\gamma}{1-f(\rho_1,\delta)}}$ );

218 iii) develop symptoms (with probability 
$$\frac{\lambda}{\alpha\beta + \lambda + \frac{\epsilon\gamma}{1 - f(\rho_1, \delta)}}$$
), or;

219 iv) be isolated (with probability 
$$\frac{\frac{\epsilon\gamma}{1-f(\rho_1,\delta)}}{\alpha\beta+\lambda+\frac{\epsilon\gamma}{1-f(\rho_1,\delta)}}$$
).

These probabilities are obtained by considering the rates at which different possible events occur in the branching process model. Presymptomatic hosts generate new infections at rate  $\alpha\beta$ , and these new infections occur in asymptomatic and presymptomatic hosts with probabilities  $\xi$  and  $1 - \xi$ , respectively. Therefore, starting from a single presymptomatic host, new asymptomatic infections occur at rate  $\xi\alpha\beta$ , whilst new presymptomatic infections occur at rate  $(1 - \xi)\alpha\beta$ .

Additionally, presymptomatic hosts develop symptoms at rate  $\lambda$ , and are isolated at rate  $\frac{\epsilon \gamma}{1-f(\rho_1,\delta)}$ .

226 The overall rate at which events occur is the sum of these individual event rates:

227 Total event rate = 
$$\alpha\beta + \lambda + \frac{\epsilon\gamma}{1 - f(\rho_1, \delta)}$$

228 For each of the four possible next events (i-iv, above), the probability that event occurs next is the

individual rate at which that event occurs divided by the total event rate, leading to the expressions

230 given.

231

- 232 We use these probabilities to condition on the event that occurs next in the branching process,
- 233 following the introduction of a single presymptomatic infectious individual into the population. If
- that event is the generation of a new asymptomatic infection, which occurs with probability
- 235  $\frac{\xi \alpha \beta}{\alpha \beta + \lambda + \frac{\varepsilon \gamma}{1 f(\rho_1, \delta)}}$ , the probability that a local outbreak subsequently does not occur is  $q_{1,0,1}$ . Applying
- analogous reasoning to the other possible events, we obtain

$$237 \qquad q_{1,0,0} = \frac{\xi \alpha \beta}{\alpha \beta + \lambda + \frac{\varepsilon \gamma}{1 - f(\rho_1, \delta)}} q_{1,0,1} + \frac{(1 - \xi) \alpha \beta}{\alpha \beta + \lambda + \frac{\varepsilon \gamma}{1 - f(\rho_1, \delta)}} q_{2,0,0} + \frac{\lambda}{\alpha \beta + \lambda + \frac{\varepsilon \gamma}{1 - f(\rho_1, \delta)}} q_{0,1,0} + \frac{\frac{\varepsilon \gamma}{1 - f(\rho_1, \delta)}}{\alpha \beta + \lambda + \frac{\varepsilon \gamma}{1 - f(\rho_1, \delta)}} q_{0,0,0}.$$

238

If there are no infectious hosts present in the population (i.e. i = j = k = 0), then a local outbreak will not occur and so  $q_{0,0,0} = 1$ . Assuming that transmission chains arising from two infectious

241 individuals are independent gives  $q_{1,0,1} = q_{1,0,0} q_{0,0,1}$  and  $q_{2,0,0} = q_{1,0,0}^2$ . Hence,

242 
$$q_{1,0,0} = a\xi q_{1,0,0} q_{0,0,1} + a(1-\xi)q_{1,0,0}^2 + bq_{0,1,0} + (1-a-b), \quad (3)$$

243 where 
$$a = \frac{\alpha\beta}{\alpha\beta + \lambda + \frac{\epsilon\gamma}{1 - f(\rho_{1,\delta})}}, b = \frac{\lambda}{\alpha\beta + \lambda + \frac{\epsilon\gamma}{1 - f(\rho_{1,\delta})}}$$

245 Similarly, considering the probability of a local outbreak failing to occur starting from a single

246 symptomatic host gives

247 
$$q_{0,1,0} = \frac{\xi\beta}{\beta + \frac{\gamma}{1 - f(\rho_2, \delta)} + \mu} q_{0,1,1} + \frac{(1 - \xi)\beta}{\beta + \frac{\gamma}{1 - f(\rho_2, \delta)} + \mu} q_{1,1,0} + \frac{\frac{\gamma}{1 - f(\rho_2, \delta)} + \mu}{\beta + \frac{\gamma}{1 - f(\rho_2, \delta)} + \mu} q_{0,0,0}$$

As before, noting that  $q_{0,0,0} = 1$  and assuming that different infection lineages are independent

249 leads to

250 
$$q_{0,1,0} = c\xi q_{01,0}q_{0,0,1} + c(1-\xi)q_{1,0,0}q_{0,1,0} + (1-c), \qquad (4)$$

251 where 
$$c = \frac{\beta}{\beta + \frac{\gamma}{1 - f(\rho_2, \delta)} + \mu}$$
.

252 Finally, considering the probability of a local outbreak failing to occur starting from a single253 asymptomatic host gives

$$q_{0,0,1} = d\xi q_{0,0,1}^2 + d(1-\xi)q_{1,0,0}q_{0,0,1} + (1-d),$$
(5)

255 where 
$$d = \frac{\eta\beta}{\eta\beta + \nu + \frac{\epsilon\gamma}{1 - f(\rho_1, \delta)}}$$
.

256

254

Equations (3), (4) and (5) may be combined to give a single quartic equation for  $q_{0,0,1}$ , yielding four sets of solutions for  $q_{1,0,0}$ ,  $q_{0,1,0}$  and  $q_{0,0,1}$  (see Supplementary Text S1). It is straightforward to verify that  $q_{1,0,0} = q_{0,1,0} = q_{0,0,1} = 1$  is always a solution, and further solutions can be found numerically. The appropriate solution to take is the minimal non-negative real solution  $q_{1,0,0} =$  $q_{1,0,0}^*$ ,  $q_{0,1,0} = q_{0,1,0}^*$ ,  $q_{0,0,1} = q_{0,0,1}^*$  (see Supplementary Text S1). Then, the probability of a local outbreak occurring beginning from a single presymptomatic host is given by  $p_{1,0,0} = 1 - q_{1,0,0}^*$ ,

with equivalent expressions holding for  $p_{0,1,0}$  and  $p_{0,0,1}$  (the probability of a local outbreak

265 occurring beginning from a single symptomatic host or a single asymptomatic host, respectively).

267	Throughout, we consider the probability $p$ of a local outbreak starting from a single
268	nonsymptomatic host entering the population, accounting for the possibility that the
269	nonsymptomatic host is either presymptomatic or asymptomatic:
270	$p = (1 - \xi)p_{1,0,0} + \xi p_{0,0,1}.$
271	
272	3. Results
273	3.1 Probability of a local outbreak
274	We considered the effect of $R_0$ and the duration of the presymptomatic and asymptomatic periods
275	on the probability of a local outbreak when a nonsymptomatic host enters a new host population
276	(Fig 2). We examined presymptomatic periods of length $1/\lambda = 1$ day, $1/\lambda = 2$ days and $1/\lambda = 4$
277	days; in each case, the duration of the asymptomatic period $(1/\nu \text{ days})$ was adjusted so that the
278	relative proportion of infections arising from asymptomatic hosts compared to presymptomatic
279	hosts remained fixed ( $K_a/K_p = 0.218$ , as in the baseline case). If instead nonsymptomatic
280	infections are not accounted for, the infectious period follows an exponential distribution and the
281	probability of a local outbreak is given by $p = 1 - 1/R_0$ (red dash-dotted line in Fig 2A).
282	Including nonsymptomatic infection in the model therefore led to an increased risk of a local
283	outbreak in the absence of surveillance intensification (Fig 2A).
284	



286 Fig 2. The effect of the duration of the presymptomatic and asymptomatic periods on the probability 287 of a local outbreak (p), starting from a single nonsymptomatic host. A. The probability of a local 288 outbreak as a function of the basic reproduction number  $R_0$ , for presymptomatic periods of lengths  $1/\lambda = 1$ 289 day (purple),  $1/\lambda = 2$  days (blue) and  $1/\lambda = 4$  days (green) in the absence of enhanced surveillance ( $\rho_1 =$ 290  $\rho_2 = 0$ ). In each case, the duration of the asymptomatic period  $(1/\nu)$  is adjusted so that the relative 291 proportion of infections arising from asymptomatic hosts compared to presymptomatic hosts remains 292 constant ( $K_a/K_p = 0.218$ , as in the baseline case). The red dash-dotted line indicates the probability of a 293 local outbreak in the absence of nonsymptomatic transmission. The vertical grey dotted line indicates  $R_0 =$ 294 3, the baseline value used throughout. B. The probability of a local outbreak as a function of the surveillance 295 intensification efforts  $\rho_1$  and  $\rho_2$ , for  $1/\lambda = 1$  day. C. The analogous figure to B but with  $1/\lambda = 2$  days. D. 296 The analogous figure to B but with  $1/\lambda = 4$  days. Red dotted lines indicate contours of constant local 297 outbreak probability (i.e. lines on which the probability of a local outbreak takes the values shown). The

298 value of  $\beta$  is varied in each panel to fix  $R_0 = 3$ . All other parameter values are held fixed at the values in 299 Table 1 (except where stated).

300

We then considered the dependence of the probability of a local outbreak on the intensity of surveillance targeting nonsymptomatic and symptomatic hosts (Fig 2B-D). The maximum value of the surveillance intensification effort that we considered (given by  $\rho_1$  or  $\rho_2$  values of 20) corresponded to a 76% reduction in the expected time to isolation (blue line in Fig 1B), i.e. a 76% reduction in  $\frac{1}{\epsilon_V}$  or  $\frac{1}{\gamma}$ .

306

307 The length of the presymptomatic and asymptomatic periods significantly affected the dependence 308 of the probability of a local outbreak on the level of surveillance targeted at nonsymptomatic and 309 symptomatic hosts. In Fig 2B, in which the duration of the presymptomatic period was 1 day, 310 increasing surveillance targeted at nonsymptomatic hosts ( $\rho_1$ ) had a limited effect on the 311 probability of a local outbreak, while increasing surveillance targeted at symptomatic hosts ( $\rho_2$ ) 312 had a more significant effect. For example, increasing the surveillance effort targeted at nonsymptomatic hosts to  $\rho_1 = 5$  (a 67% reduction in the time to isolation) only reduced the 313 314 probability of a local outbreak from 0.730 to 0.716, whereas the equivalent effort targeted at 315 symptomatic hosts ( $\rho_2 = 5$ ) reduced the probability to 0.630. As shown in Figs 3C and D, 316 however, when the presymptomatic and asymptomatic periods were longer, the benefit of directing 317 surveillance resources towards detecting nonsymptomatic individuals increased. This was because 318 longer presymptomatic and asymptomatic periods increased the proportion of infections generated by nonsymptomatic individuals  $(K_p + K_a, \text{ see equations (1) and (2)})$ ; a presymptomatic period of 1 319 day, 2 days and 4 days corresponded to values of  $K_p + K_a$  equal to 0.424, 0.595 and 0.746, 320 321 respectively.

322

### 323 **3.2 Optimising surveillance enhancement**

324 We next considered in more detail the impact of surveillance targeted at nonsymptomatic hosts 325  $(\rho_1)$  relative to the impact of surveillance targeted at symptomatic hosts  $(\rho_2)$ . For our baseline 326 parameter values, we considered the probability of a local outbreak starting from a single imported 327 nonsymptomatic individual for a range of values of  $\rho_1$  and  $\rho_2$ . We calculated the steepest descent contours (white lines in Fig 3A) numerically using a gradient maximisation approach, in which at 328 329 each point the contour direction was determined by minimising the local outbreak probability over 330 a fixed search radius (see Supplementary Text S2 and Supplementary Fig S2). These contours indicate how  $\rho_1$  and  $\rho_2$  should be altered to maximise the reduction in the probability of a local 331 332 outbreak. In this case, enhancing surveillance targeting both symptomatic and nonsymptomatic 333 hosts is always optimal (the steepest descent contours are neither horizontal nor vertical).



336 Fig 3. Optimal surveillance strategies to reduce the probability of a local outbreak (p) starting from a 337 single nonsymptomatic host. A. The local outbreak probability for different values of  $\rho_1$  and  $\rho_2$ , with the 338 steepest descent contours overlaid (white lines). For the maximum reduction in the probability of a local 339 outbreak at each point, surveillance must be enhanced for both nonsymptomatic and symptomatic 340 individuals, with different levels of prioritisation depending on the current values of  $\rho_1$  and  $\rho_2$ . B. Values of 341  $\rho_1$  and  $\rho_2$  for which increasing surveillance for nonsymptomatic hosts (i.e. increasing  $\rho_1$ ) is more effective 342 at reducing the local outbreak probability than increasing surveillance for symptomatic hosts (i.e. increasing 343  $\rho_2$ ) (green region) and vice versa (blue region). The white line represents the steepest descent contour 344 starting from  $\rho_1 = \rho_2 = 0$ , under the constraint that surveillance can only be enhanced for either 345 symptomatic or nonsymptomatic hosts at any time. The diagonal section of the steepest descent contour is 346 made up of small horizontal and vertical sections. C. Strategies for minimising the local outbreak probability 347 for a given fixed total surveillance effort ( $\rho_1 + \rho_2 = C$ ). Red dotted lines indicate contours on which  $\rho_1$  + 348  $\rho_2$  is constant (i.e. lines on which  $\rho_1 + \rho_2$  takes the values shown); red circles indicate the points along these

349	contours at which the local outbreak probability is minimised. The white line indicates the optimal
350	surveillance enhancement strategy if the maximum possible surveillance level (i.e. the maximum value of
351	$\rho_1 + \rho_2 = C$ ) is increased. D. Strategies for minimising the surveillance effort required to achieve a pre-
352	specific risk level (an "acceptable" local outbreak probability). Red dotted lines indicate contours of
353	constant local outbreak probability (i.e. lines on which the probability of a local outbreak takes the values
354	shown); red circles indicate the points along these contours at which the total surveillance effort $\rho_1 + \rho_2$ is
355	minimised. The white line indicates the optimal strategy to follow if the pre-specified risk level is increased
356	or reduced.

357

358 We then considered a scenario in which, at any time, it is only possible to direct resources towards 359 enhancing surveillance of either nonsymptomatic individuals or symptomatic individuals (e.g. 360 antigen testing of nonsymptomatic contacts of known infectious individuals, or screening for symptomatic individuals at public events). In Fig 3B, the blue region represents values of  $\rho_1$  and 361  $\rho_2$  for which enhancing surveillance targeting symptomatic hosts (i.e. increasing  $\rho_2$ ) leads to a 362 363 larger reduction in the local outbreak probability than enhancing surveillance targeting 364 nonsymptomatic hosts (i.e. increasing  $\rho_1$ ). In contrast, in the green region, enhancing surveillance 365 of nonsymptomatic individuals is more effective than enhancing surveillance of symptomatic individuals. The white line represents the steepest descent contour starting from  $\rho_1 = \rho_2 = 0$ , 366 367 under the constraint that surveillance can only be enhanced for symptomatic or nonsymptomatic 368 hosts at any time.

369

Practical deployment of surveillance is often subject to logistical constraints, and policy-makers
may wish to design surveillance strategies to achieve a specific objective – for example, to
maximise the effectiveness of limited resources or to minimise the cost of achieving a desired
outcome. We therefore also considered the following two examples of such objectives.

374

375	Objective 1: Minimise the probability of a local outbreak for a fixed total surveillance effort.
376	First, we considered the question: given a fixed maximum surveillance effort ( $\rho_1 + \rho_2 = C$ ), how
377	should surveillance be targeted at nonsymptomatic and symptomatic hosts? This involves setting
378	the values of $\rho_1$ and $\rho_2$ to minimise the local outbreak probability. The optimal strategies in this
379	case are shown in Fig 3C. The red dotted lines represent contours along which the total
380	surveillance effort $\rho_1 + \rho_2$ is held constant (i.e. different values of <i>C</i> ). On each contour, the red
381	circle indicates the point at which the local outbreak probability is minimised.
382	
383	If surveillance resources are increased (i.e. $C$ increases), a further question is how surveillance
384	should then be increased. In Fig 3C, the white line represents the contour of steepest descent,
385	under the constraint that the total change in surveillance effort $(\rho_1 + \rho_2)$ is held constant at each
386	step (rather than a constant search radius, as in Fig 3A – for more details, see Supplementary Text
387	S2 and Supplementary Fig S2). This contour coincides exactly with that shown in Fig 3B.
388	
389	These results indicate that, if surveillance resources are such that $C$ is greater than 2.8
390	(corresponding to a 59% reduction in time to isolation of symptomatic hosts), the optimal
391	surveillance strategy involves both enhanced surveillance of symptomatic individuals and
392	nonsymptomatic individuals (the red dots correspond to strictly positive values of both $\rho_1$ and $\rho_2$ ,
393	unless C is less than 2.8).
394	
395	Objective 2: Minimise the total surveillance effort to achieve a pre-specified reduction in the
396	probability of a local outbreak. Second, we considered the question: given a pre-specified
397	acceptable risk level (i.e. probability of a local outbreak), how should the surveillance level

398 targeted at nonsymptomatic and symptomatic hosts be chosen? This involves choosing  $\rho_1$  and  $\rho_2$ to minimise  $\rho_1 + \rho_2$  along a given contour corresponding to a fixed local outbreak probability (red 399 400 dotted lines in Fig 3D). On each contour, the red circle indicates the point along that contour at which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. These optimal points also lie exactly 401 402 along the line on which enhancing surveillance targeted at symptomatic hosts is equally effective 403 compared to enhancing surveillance targeted at nonsymptomatic hosts. 404 405 As long as the target local outbreak probability is less than 0.69, optimal surveillance involves 406 enhanced surveillance of nonsymptomatic individuals as well as symptomatic individuals. For 407 example, in order to reduce the local outbreak probability to 0.6, the optimal approach is to deploy 408 resources such that  $\rho_1 = 12.4$  (a 74% reduction in time to isolation of nonsymptomatic individuals) and  $\rho_2 = 18.0$  (a 76% reduction in time to isolation of symptomatic individuals). 409 410 411 Plots analogous to Fig 3D in which the parameters were varied from their baseline values are 412 shown in Supplementary Figs S3-12. In each case that we considered, our main finding was 413 unchanged. There always exists a threshold local outbreak probability such that, if the target local 414 outbreak probability is below this threshold, the optimal strategy for further reduction in the local 415 outbreak probability involves enhancing surveillance targeting both nonsymptomatic and 416 symptomatic individuals. 417 4. Discussion 418

A key component of infectious disease epidemic management is inferring the risk of outbreaks in
different locations [5-8, 11, 41, 42]. Surveillance and control strategies can be introduced to reduce
the risk that imported cases will lead to local outbreaks [12, 13, 43-46]. However, for a range of

pathogens, public health measures are hindered by nonsymptomatic infectious hosts who can
transmit the pathogen yet are challenging to detect [16, 42, 44, 47-49].

424

425 Here, we showed how the probability of a local outbreak can be estimated using a branching 426 process model that accounts for transmission from nonsymptomatic infected individuals (Fig 1). 427 The model can be used to assess the local outbreak probability for different surveillance strategies 428 that target nonsymptomatic or symptomatic hosts (Fig 2). Previous studies have shown that 429 detection of nonsymptomatic infections can be a key component of epidemic forecasting [42] and 430 containment [44], and have demonstrated the benefits of identifying and isolating infectious 431 nonsymptomatic hosts to reduce transmission [16, 17]. We focused instead on investigating how 432 surveillance should be targeted at nonsymptomatic or symptomatic hosts in order to reduce the 433 probability that cases imported to new locations will trigger a local outbreak (Fig 3A,B). We also 434 showed how the optimal surveillance level targeting these two groups can be assessed when 435 surveillance resources are limited and policy-makers have specific objectives (Fig 3C,D). In each 436 case, our main conclusion was that surveillance for nonsymptomatic infected hosts ( $\rho_1 > 0$ ) can 437 be an important component of reducing the local outbreak risk during epidemics. This result has 438 broad implications, and our analysis could be extended to assess the potential for containing 439 outbreaks at their source using a range of specific interventions targeting symptomatic and 440 nonsymptomatic hosts.

441

Our goal here was to use the simplest possible model to explore the effects of surveillance of
nonsymptomatic and symptomatic individuals on the risk of local outbreaks. However, this model
is not without its limitations. One area of uncertainty is the precise values of the parameters
governing pathogen transmission and control. In this article, we chose a baseline set of parameter

446 values that is consistent with the findings of studies conducted during the COVID-19 pandemic, 447 although constructing a detailed transmission model for this pandemic was not our main focus. For 448 example, we set the relative rates at which presymptomatic and asymptomatic individuals generate 449 new infections compared to symptomatic individuals so that 48.9% of transmissions arise from 450 presymptomatic infectors, and 10.6% arise from asymptomatic infectors [16]. While this is in line 451 with reported estimates [50, 51], there is substantial variation between studies. Similarly, the 452 proportion of individuals who experience a fully asymptomatic course of infection (denoted by  $\xi$ 453 in our model) is subject to a considerable degree of uncertainty. Here, we chose  $\xi = 0.2$  as the 454 baseline value [32-34] but estimates in the literature range from 0.04 to over 0.8 [33, 52-54]. We 455 therefore also conducted sensitivity analyses in which we explored a range of different values of 456 model parameters (Supplementary Text S3 and Supplementary Figs S3-12). In each case that we 457 considered, our main conclusion was unchanged: surveillance of nonsymptomatic individuals can 458 contribute to reducing the risk of local outbreaks. This result is expected to hold for epidemics of 459 any pathogen for which nonsymptomatic individuals contribute significantly to transmission. 460

461 For our modelling approach to be used to make precise quantitative predictions during epidemics, 462 it would be necessary to update the model to include the range of different specific surveillance 463 and control interventions that are in place. For example, detection of nonsymptomatic infected 464 individuals is facilitated by contact tracing and antigen testing, which are carried out routinely 465 during epidemics and can be included in models explicitly [12, 44, 55, 56]. Reductions in contacts 466 due to social distancing strategies and school or workplace closures could also be accounted for 467 [57, 58], although such interventions are often introduced after a local outbreak has begun rather 468 than in the initial phase of a potential local outbreak as considered here. We modelled the level of 469 surveillance targeted at nonsymptomatic and symptomatic hosts in a simple way, using a function

470 describing the relationship between surveillance effort and effectiveness (Fig 1B). We assumed 471 that this general functional relationship could be applied to interventions targeting both 472 symptomatic and nonsymptomatic hosts, accounting for logistical differences in the ease of 473 targeting either group by scaling the effectiveness of surveillance for nonsymptomatic hosts using 474 the parameter  $\varepsilon$  (results are shown for different values of  $\varepsilon$  in Supplementary Fig S8). In principle, 475 it would be possible to include entirely different functional forms describing the relationship 476 between surveillance effort and effectiveness for strategies targeting symptomatic and 477 nonsymptomatic individuals, and these could be tailored to the effects of particular interventions. 478 If different public health measures are included in the model explicitly, then it would be possible 479 to increase the accuracy of assessments of the relative public health benefits of specific 480 interventions that only target symptomatic individuals (e.g. screening for passengers with 481 heightened temperatures at airports [59, 60]) compared to interventions that also target 482 nonsymptomatic hosts (e.g. travel bans or quarantine of all inbound passengers [61, 62]). Of 483 course, this would require data from which the relative effectiveness of different measures could 484 be inferred. 485

486 The underlying transmission model could also be extended to include additional realism in several 487 ways. Transmission dynamics are influenced by marked heterogeneities in the patterns of contacts 488 between individuals in different age groups [63, 64], and, for COVID-19, susceptibility to 489 infection, the likelihood of developing symptoms, and the average severity of those symptoms 490 increase with age [65, 66]. Age-dependent variation in the proportion of asymptomatic cases in 491 particular implies that the optimal balance of surveillance between symptomatic and 492 nonsymptomatic hosts may differ between age groups. An age-structured version of the model 493 presented here is a focus of our ongoing research. Similarly, for a range of infectious diseases, the

494	distribution characterising the number of secondary infections generated by each infected host (the
495	offspring distribution) exhibits a high degree of overdispersion [67-70]. For a fixed value of $R_0$ , a
496	higher degree of overdispersion increases the likelihood that initial cases will fade out without
497	leading to a local outbreak [71, 72], and suggests that greater reductions in local outbreak risks
498	could theoretically be achieved for the same surveillance effort, if potential superspreaders or
499	superspreading events can be identified and targeted.
500	
501	Despite the necessary simplifications, we have shown how the risk of local outbreaks can be
502	estimated during epidemics using a branching process model that includes nonsymptomatic
503	infectious hosts explicitly. Determining the extent to which nonsymptomatic individuals contribute
504	to transmission is essential early in emerging epidemics of a novel pathogen. As we have shown, if
505	transmissions occur from nonsymptomatic infectors, dedicating surveillance resources towards
506	finding nonsymptomatic cases can be an important component of public health measures that aim
507	to prevent local outbreaks.
508	
509	Acknowledgements
510	Thank you to Andrew Wood and Charles Tolkien-Gillett for proofreading.
511	
512	Funding
513	FALR acknowledges funding from the Biotechnology and Biological Sciences Research Council
514	(UKRI-BBSRC), grant number BB/M011224/1. SF and RNT acknowledge funding from the
515	Wellcome Trust, grant number 210758/Z/18/Z. RNT also acknowledges funding from Christ
516	Church (University of Oxford) via a Junior Research Fellowship. CAD acknowledges funding
517	from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly

- 518 funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth &
- 519 Development Office (FCDO) under the MRC/FCDO Concordat agreement, and is also part of the
- 520 EDCTP2 programme supported by the European Union.
- 521

## 522 **References**

- 523 [1] Bloom, D.E. & Cadarette, D. 2019 Infectious Disease Threats in the Twenty-First Century:
- 524 Strengthening the Global Response. *Front. Immunol.* **10**. (doi:10.3389/fimmu.2019.00549).
- 525 [2] Morens, D.M. & Fauci, A.S. 2013 Emerging Infectious Diseases: Threats to Human Health
- and Global Stability. *Public Library of Science: Pathogens* 9, e1003467.
- 527 (doi:10.1371/journal.ppat.1003467).
- 528 [3] Sigfrid, L., Maskell, K., Bannister, P.G., Ismail, S.A., Collinson, S., Regmi, S., Blackmore, C.,
- 529 Harriss, E., Longuere, K.-S., Gobat, N., et al. 2020 Addressing challenges for clinical research
- responses to emerging epidemics and pandemics: a scoping review. *BMC Med.* **18**, 190-190.
- 531 (doi:10.1186/s12916-020-01624-8).
- 532 [4] Thompson, R.N. & Brooks-Pollock, E. 2019 Detection, forecasting and control of infectious
- 533 disease epidemics: modelling outbreaks in humans, animals and plants. *Philos. Trans. R. Soc.*
- 534 Lond., B, Biol. Sci. 374, 20190038-20190038. (doi:10.1098/rstb.2019.0038).
- 535 [5] Althaus, C.L., Low, N., Musa, E.O., Shuaib, F. & Gsteiger, S. 2015 Ebola virus disease
- 536 outbreak in Nigeria: Transmission dynamics and rapid control. *Epidemics* **11**, 80-84.
- 537 (doi:10.1016/j.epidem.2015.03.001).
- 538 [6] Boldog, P., Tekeli, T., Vizi, Z., Denes, A., Bartha, F.A. & Rost, G. 2020 Risk Assessment of
- 539 Novel Coronavirus COVID-19 Outbreaks Outside China. J. Clin. Med. 9, 571.
- 540 (doi:doi.org/10.3390/jcm9020571).

- 541 [7] Daon, Y., Thompson, R.N. & Obolski, U. 2020 Estimating COVID-19 outbreak risk through
- 542 air travel. J. Travel Med. 27. (doi:10.1093/jtm/taaa093).
- 543 [8] Lashari, A.A. & Trapman, P. 2018 Branching process approach for epidemics in dynamic
- 544 partnership network. J. Math. Biol. 76, 265-294. (doi:10.1007/s00285-017-1147-0).
- 545 [9] Nishiura, H., Cook, A.R. & Cowling, B.J. 2011 Assortativity and the Probability of Epidemic
- 546 Extinction: A Case Study of Pandemic Influenza A (H1N1-2009). Interdiscip. Perspect. Infect.
- 547 Dis. 2011, 194507-194507. (doi:10.1155/2011/194507).
- 548 [10] Thompson, R.N., Jalava, K. & Obolski, U. 2019 Sustained transmission of Ebola in new
- 549 locations: more likely than previously thought. *The Lancet Infectious Diseases* **19**, 1058-1059.
- 550 (doi:10.1016/S1473-3099(19)30483-9).
- 551 [11] Thompson, R.N., Thompson, C.P., Pelerman, O., Gupta, S. & Obolski, U. 2019 Increased
- 552 frequency of travel in the presence of cross-immunity may act to decrease the chance of a global
- 553 pandemic. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 374, 20180274. (doi:10.1098/rstb.2018.0274).
- 554 [12] Hellewell, J., Abbott, S., Gimma, A., Bosse, N.I., Jarvis, C.I., Russell, T.W., Munday, J.D.,
- 555 Kucharski, A.J., Edmunds, W.J., Sun, F., et al. 2020 Feasibility of controlling COVID-19
- outbreaks by isolation of cases and contacts. *The Lancet Global Health* **8**, e488-e496.
- 557 (doi:10.1016/S2214-109X(20)30074-7).
- 558 [13] Thompson, R.N. 2020 Novel Coronavirus Outbreak in Wuhan, China, 2020: Intense
- 559 Surveillance Is Vital for Preventing Sustained Transmission in New Locations. Journal of Clinical
- 560 *Medicine* **9**, 498. (doi:10.3390/jcm9020498).
- 561 [14] Lauer, S.A., Grantz, K.H., Bi, Q., Jones, F.K., Zheng, Q., Meredith, H.R., Azman, A.S.,
- 562 Reich, N.G. & Lessler, J. 2020 The Incubation Period of Coronavirus Disease 2019 (COVID-19)
- 563 From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. 172,
- 564 577-582. (doi:10.7326/M20-0504).

- 565 [15] McAloon, C., Collins, A., Hunt, K., Barber, A., Byrne, A.W., Butler, F., Casey, M., Griffin,
- 566 J., Lane, E., McEvoy, D., et al. 2020 Incubation period of COVID-19: a rapid systematic review
- and meta-analysis of observational research. *BMJ Open* **10**, e039652. (doi:10.1136/bmjopen-2020-
- 568 039652).
- 569 [16] Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Abeler-Dorner, L., Parker, M.,
- 570 Bonsall, D. & Fraser, C. 2020 Quantifying SARS-CoV-2 transmission suggests epidemic control
- 571 with digital contact tracing. *Science* **368**, eabb6936. (doi:10.1126/science.abb6936).
- 572 [17] Moghadas, S.M., Fitzpatrick, M.C., Sah, P., Pandey, A., Shoukat, A., Singer, B.H. & Galvani,
- 573 A. 2020 The implications of silent transmission for the control of COVID-19 outbreaks. *Proc.*
- 574 Natl. Acad. Sci. U. S. A. 117, 17513-17515. (doi:10.1073/pnas.2008373117).
- 575 [18] Tindale, L.C., Stockdale, J.E., Coombe, M., Garlock, E.S., Lau, W.Y.V., Saraswat, M.,
- 576 Zhang, L., Chen, D., Wallinga, J. & Colijn, C. 2020 Evidence for transmission of COVID-19 prior
- 577 to symptom onset. *eLife* **9**, e57149. (doi:10.7554/eLife.57149).
- 578 [19] Tong, Z.-D., Tang, A., Li, K.-F., Li, P., Wang, H.-L., Yi, J.-P., Zhang, Y.-L. & Yan, J.-B.
- 579 2020 Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020.
- 580 *Emerging Infectious Diseases* **26**, 1052-1054. (doi:10.3201/eid2605.200198).
- 581 [20] Wei, W.E., Li, Z., Chiew, C.J., Yong, S.E., Toh, M.P. & Lee, V.J. 2020 Presymptomatic
- 582 Transmission of SARS-CoV-2 Singapore, January 23–March 16, 2020. Morbidity and
- 583 Mortality Weekly Report 69, 411-415. (doi:10.15585/mmwr.mm6914e1external icon).
- 584 [21] Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L. & Wang, M. 2020 Presumed
- 585 Asymptomatic Carrier Transmission of COVID-19. J. Am. Med. Assoc. 323, 1406-1407.
- 586 (doi:10.1001/jama.2020.2565).

- 587 [22] Furukawa, N.W., Brooks, J.T. & Sobel, J. 2020 Evidence Supporting Transmission of Severe
- 588 Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. *Emerging*
- 589 Infectious Diseases 26, e201595. (doi:10.3201/eid2607.201595).
- 590 [23] Anderson, D. & Watson, R. 1980 On the spread of a disease with gamma distributed latent
- 591 and infectious periods. *Biometrika* 67, 191-198. (doi:10.1093/biomet/67.1.191).
- 592 [24] Bartlett, M.S. 1964 The Relevance of Stochastic Models for Large-Scale Epidemiological
- 593 Phenomena. J. Roy. Stat. Soc. Ser. C. (Appl. Stat.) 13, 2-8. (doi:10.2307/2985217).
- 594 [25] Craft, M.E., Beyer, H.L. & Haydon, D.T. 2013 Estimating the Probability of a Major
- 595 Outbreak from the Timing of Early Cases: An Indeterminate Problem? *PLoS One* **8**, e57878-
- 596 e57878. (doi:10.1371/journal.pone.0057878).
- 597 [26] Lloyd, A.L., Zhang, J. & Root, A.M. 2007 Stochasticity and heterogeneity in host-vector
- 598 models. J. R. Soc. Interface 4, 851-863. (doi:10.1098/rsif.2007.1064).
- 599 [27] Matthews, L., Haydon, D.T., Shaw, D.J., Chase-Topping, M.E., Keeling, M.J. & Woolhouse,
- 600 M.E.J. 2003 Neighbourhood control policies and the spread of infectious diseases. *Proceedings of*
- 601 *the Royal Society B: Biological Sciences* **270**, 1659-1666. (doi:10.1098/rspb.2003.2429).
- 602 [28] Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J. & Hsueh, P.-R. 2020 Severe acute respiratory
- 603 syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The
- 604 epidemic and the challenges. *International Journal of Antimicrobial Agents* 55, 105924.
- 605 (doi:10.1016/j.ijantimicag.2020.105924).
- 606 [29] Liu, Y., Gayle, A.A., Wilder-Smith, A. & Rocklov, J. 2020 The reproductive number of
- 607 COVID-19 is higher compared to SARS coronavirus. *Journal of Travel Medicine* 27, taaa021.
- 608 (doi:10.1093/jtm/taaa021).

- 609 [30] Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y. & Li, Y. 2020 The epidemiology, diagnosis
- and treatment of COVID-19. *International Journal of Antimicrobial Agents* **55**, 105955-105955.
- 611 (doi:10.1016/j.ijantimicag.2020.105955).
- 612 [31] Zhao, S., Lin, Q., Ran, J., Musa, S.S., Yang, G., Wang, W., Lou, Y., Gao, D., Yang, L., He,
- 613 D., et al. 2020 Preliminary estimation of the basic reproduction number of novel coronavirus
- 614 (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the
- 615 outbreak. International Journal of Infectious Diseases 92, 214-217.
- 616 (doi:10.1016/j.ijid.2020.01.050).
- 617 [32] Buitrago-Garcia, D., Egli-Gany, D., Counotte, M.J., Hossman, S., Imeri, H., Ipekci, A.M.,
- 618 Salanti, G. & Low, N. 2020 Occurrence and transmission potential of asymptomatic and
- 619 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS
- 620 *Med.* 17, e1003346. (doi:10.1371/journal.pmed.1003346).
- 621 [33] Byambasuren, O., Cardona, M., Bell, K., Clark, J., McLaws, M.-L. & Glasziou, P. 2020
- 622 Estimating the extend of asymptomatic COVID-19 and its potential for community transmission:
- 623 Systematic review and meta-analysis. *JAMMI* **5**, 223-234. (doi:10.3138/jammi-2020-0030).
- 624 [34] He, J., Guo, Y., Mao, R. & Zhang, J. 2020 Proportion of asymptomatic coronavirus disease
- 625 2019: A systematic review and meta-analysis. J. Med. Virol. 93, 820-830.
- 626 (doi:10.1002/jmv.26326).
- 627 [35] Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau,
- 628 E.H.Y., Wong, J.Y., et al. 2020 Early Transmission Dynamics in Wuhan, China, of Novel
- 629 Coronavirus–Infected Pneumonia. N. Engl. J. Med. 382, 1199-1207.
- 630 (doi:10.1056/NEJMoa2001316).
- 631 [36] Arons, M.M., Hatfield, K.M., Reddy, S.C., Kimball, A., James, A., Jacobs, J.R., Taylor, J.,
- 632 Spicer, K., Bardossy, A.C., Oakley, L.P., et al. 2020 Presymptomatic SARS-CoV-2 Infections and

- 633 Transmission in a Skilled Nursing Facility. *The New England Journal of Medicine* **382**, 2081-
- 634 2090. (doi:10.1056/NEJMoa2008457).
- 635 [37] Bullard, J., Dust, K., Funk, D., Strong, J.E., Alexander, D., Garnett, L., Boodman, C., Bello,
- 636 A., Hedley, A., Schiffman, Z., et al. 2020 Predicting Infectious Severe Acute Respiratory
- 637 Syndrome Coronavirus 2 From Diagnostic Samples. *Clinical Infectious Diseases*, ciaa638.
- 638 (doi:10.1093/cid/ciaa638).
- 639 [38] Wolfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M.A.,
- 640 Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., et al. 2020 Virological assessment of
- 641 hospitalized patients with COVID-2019. *Nature* **581**, 465-469. (doi:10.1038/s41586-020-2196-x).
- 642 [39] Nasell, I. 1995 The Threshold Concept in Stochastic Epidemic and Endemic Models. In
- 643 Epidemic Models: Their Structure and Relation to Data (ed. D. Mollison), pp. 71-83. Cambridge,
- 644 UK, Cambridge University Press.
- [40] Britton, T. 2010 Stochastic epidemic models: A survey. *Math. Biosci.* 225, 24-35.
- 646 (doi:10.1016/j.mbs.2010.01.006).
- 647 [41] Thompson, R.N., Gilligan, C.A. & Cunniffe, N.J. 2020 Will an outbreak exceed available
- resources for control? Estimating the risk from invading pathogens using practical definitions of a
- 649 severe epidemic. J. R. Soc. Interface 17. (doi:10.1098/rsif.2020.0690).
- 650 [42] Thompson, R.N., Gilligan, C.A. & Cunniffe, N.J. 2016 Detecting Presymptomatic Infection
- 651 Is Necessary to Forecast Major Epidemics in the Earliest Stages of Infectious Disease Outbreaks.
- 652 *PLoS Comput. Biol.* **12**, e1004836. (doi:10.1371/journal.pcbi.1004836).
- 653 [43] Charleston, B., Bankowski, B.M., Gubbins, S., Chase-Topping, M.E., Schley, D., Howey, R.,
- Barnett, P.V., Gibson, D., Juleff, N.D. & Woolhouse, M.E.J. 2011 Relationship Between Clinical
- 655 Signs and Transmission of an Infectious Disease and the Implications for Control. Science 332,
- 656 726-729. (doi:10.1126/science.1199884).

- 657 [44] Fraser, C., Riley, S., Anderson, R.M. & Ferguson, N.M. 2004 Factors that make an infectious
- disease outbreak controllable. Proc. Natl. Acad. Sci. U. S. A. 101, 6146-6151.
- 659 (doi:10.1073/pnas.0307506101).
- 660 [45] Martinez, L. 2000 Global infectious disease surveillance. Int. J. Infect. Dis. 4, 222-228.
- 661 (doi:10.1016/s1201-9712(00)90114-0).
- 662 [46] Milinovich, G.J., Williams, G.M., Clements, A.C.A. & Hu, W. 2014 Internet-based
- 663 surveillance systems for monitoring emerging infectious diseases. *The Lancet Infectious Diseases*
- 664 **14**, 160-168. (doi:10.1016/S1473-3099(13)70244-5).
- 665 [47] Gu, Y., Komiya, N., Kamiya, H., Yasui, Y., Taniguchi, K. & Okabe, N. 2011 Pandemic
- 666 (H1N1) 2009 Transmission during Presymptomatic Phase, Japan. Emerging Infectious Diseases
- 667 **17**, 1737-1739. (doi:10.3201/eid1709.101411).
- 668 [48] Ip, D.K.M., Lau, L.L.H., Leung, N.H.L., Fang, V.J., Chan, K.-H., Chu, D.K.W., Leung,
- 669 G.M., Peiris, J.S.M., Uyeki, T.M. & Cowling, B.J. 2016 Viral Shedding and Transmission
- 670 Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community.
- 671 Clin. Infect. Dis. 64, 736-742. (doi:10.1093/cid/ciw841).
- [49] ten Bosch, Q.A., Clapham, H.E., Lambrechts, L., Duong, V., Buchy, P., Althouse, B.M.,
- 673 Lloyd, A.L., Waller, L.A., Morrison, A.C., Kitron, U., et al. 2018 Contributions from the silent
- majority dominate dengue virus transmission. *PLos Pathog.* 14, e1006965-e1006965.
- 675 (doi:10.1371/journal.ppat.1006965).
- 676 [50] He, X., Lau, E.H.Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y.,
- Tan, X., et al. 2020 Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat.*
- 678 Med. 26, 672-675. (doi:10.1038/s41591-020-0869-5).

- 679 [51] Ren, X., Li, Y., Yang, X., Li, Z., Cui, J., Zhu, A., Zhao, H., Yu, J., Nie, T., Ren, M., et al.
- 680 2020 Evidence for pre-symptomatic transmission of coronavirus disease 2019 (COVID-19) in
- 681 China. Influenza Other Respi. Viruses, 1-9. (doi:10.1111/irv.12787).
- 682 [52] Yanes-Lane, M., Winters, N., Fregonese, F., Bastos, M., Perlman-Arrow, S., Campbell, J.R.
- 683 & Menzies, D. 2020 Proportion of asymptomatic infection among COVID-19 positive persons and
- 684 their transmission potential: A systematic review and meta-analysis. *PLoS One* 15.
- 685 (doi:10.1371/journal.pone.0241536).
- 686 [53] Meyerowitz, E.A., Richterman, A., Bogoch, I.I., Low, N. & Cevik, M. 2020 Towards an
- 687 accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-
- 688 2. The Lancet Infectious Diseases. (doi:10.1016/S1473-3099(20)30837-9).
- 689 [54] Oran, D.P. & Topol, E.J. 2020 Prevalence of Asymptomatic SARS-CoV-2 Infection: A
- 690 Narrative Review. Ann. Intern. Med. 173, 362-367. (doi:10.7326/M20-3012).
- 691 [55] Klinkenberg, D., Fraser, C. & Heesterbeek, H. 2006 The Effectiveness of Contact Tracing in
- 692 Emerging Epidemics. *PLoS One* **1**, e12-e12. (doi:10.1371/journal.pone.0000012).
- 693 [56] Webb, G., Browne, C., Huo, X., Seydi, O., Seydi, M. & Magal, P. 2015 A Model of the 2014
- 694 Ebola Epidemic in West Africa with Contact Tracing. *PLoS Curr.* 7.
- 695 (doi:10.1371/currents.outbreaks.846b2a31ef37018b7d1126a9c8adf22a).
- 696 [57] Davies, N.G., Kucharski, A.J., Eggo, R.M., Gimma, A., Edmunds, W.J., Jombart, T.,
- 697 O'Reilly, K., Endo, A., Hellewell, J., Nightingale, E.S., et al. 2020 Effects of non-pharmaceutical
- 698 interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a
- 699 modelling study. The Lancet Public Health 5, E375-E385. (doi:10.1016/S2468-2667(20)30133-
- 700 X).
- 701 [58] Thompson, R.N. 2020 Epidemiological models are important tools for guiding COVID-19
- 702 interventions. *BMC Med.* **18**. (doi:10.1186/s12916-020-01628-4).

- 703 [59] Nishiura, H. & Kamiya, K. 2011 Fever screening during the influenza (H1N1-2009)
- pandemic at Narita International Airport, Japan. *BMC Infect. Dis.* 11, 111-111. (doi:10.1186/14712334-11-111).
- 706 [60] Quilty, B.J., Clifford, S., group, C.n.w., Flasche, S. & Eggo, R.M. 2020 Effectiveness of
- airport screening at detecting travellers infected with novel coronavirus (2019-nCoV).
- 708 *Eurosurveillance* **25**, 2000080-2000080. (doi:10.2807/1560-7917.ES.2020.25.5.2000080).
- [61] Chinazzi, M., Davis, J.T., Ajelli, M., Gioannini, C., Litvinova, M., Merler, S., y Piontti, A.P.,
- 710 Mu, K., Rossi, L., Sun, K., et al. 2020 The effect of travel restrictions on the spread of the 2019
- novel coronavirus (COVID-19) outbreak. *Science* **368**, 395-400. (doi:10.1126/science.aba9757).
- 712 [62] Dickens, B.L., Koo, J.R., Lim, J.T., Sun, H., Clapham, H.E., Wilder-Smith, A. & Cook, A.R.
- 713 2020 Strategies at points of entry to reduce importation risk of COVID-19 cases and reopen travel.
- 714 *J. Travel Med.*, taaa141-taaa141. (doi:10.1093/jtm/taaa141).
- 715 [63] Prem, K., Cook, A.R. & Jit, M. 2017 Projecting social contact matrices in 152 countries using
- 716 contact surveys and demographic data. *PLOS Computational Biology* 13, e1005697.
- 717 (doi:10.1371/journal.pcbi.1005697).
- 718 [64] Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S.,
- 719 Viboud, C., Vespignani, A., et al. 2020 Changes in contact patterns shape the dynamics of the
- 720 COVID-19 outbreak in China. *Science* **368**, 1481-1486. (doi:10.1126/science.abb8001).
- 721 [65] Kang, S.-J. & Jung, S.I. 2020 Age-Related Morbidity and Mortality among Patients with
- 722 COVID-19. J. Infect. Chemother. 52, 154-164. (doi:10.3947/ic.2020.52.2.154).
- 723 [66] Davies, N.G., Klepac, P., Liu, Y., Prem, K., Jit, M., Pearson, C.A.B., Quilty, B.J., Kucharski,
- A.J., Gibbs, H., Clifford, S., et al. 2020 Age-dependent effects in the transmission and control of
- 725 COVID-19 epidemics. *Nature Medicine* **26**, 1205-1211. (doi:10.1038/s41591-020-0962-9).

- 726 [67] Endo, A., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working
- 727 Group, Abbott, S., Kucharski, A. & Funk, S. 2020 Estimating the overdispersion in COVID-19
- transmission using outbreak sizes outside China [version 3; peer review: 2 approved]. Wellcome
- 729 *Open Research* **5**. (doi:10.12688/wellcomeopenres.15842.3).
- 730 [68] Lau, M.S.Y., Grenfell, B., Thomas, M., Bryan, M., Nelson, K. & Lopman, B. 2020
- 731 Characterizing superspreading events and age-specific infectiousness of SARS-CoV-2
- transmission in Georgia, USA. Proc. Natl. Acad. Sci. U. S. A. 117, 22430-22435.
- 733 (doi:10.1073/pnas.2011802117).
- [69] Woolhouse, M.E.J., Dye, C., Etard, J.-F., Smith, T., Charlwood, J.D., Garnett, G.P., Hagan,
- 735 P., Hii, J.L.K., Ndhlovu, P.D., Quinnell, R.J., et al. 1997 Heterogeneities in the transmission of
- 736 infectious agents: Implications for the design of control programs. *Proceedings of the National*
- 737 Academy of Sciences 94, 338-342. (doi:10.1073/pnas.94.1.338).
- 738 [70] Thompson, R.N., Hollingsworth, T.D., Isham, V., Arribas-Bel, D., Ashby, B., Britton, T.,
- 739 Challenor, P., Chappell, L.H.K., Clapham, H., Cunniffe, N.J., et al. 2020 Key questions for
- 740 modelling COVID-19 exit strategies. Proceedings of the Royal Society B: Biological Sciences 287,
- 741 20201405. (doi:10.1098/rspb.2020.1405).
- 742 [71] Lloyd-Smith, J.O., Schreiber, S.J., Kopp, P.E. & Getz, W.M. 2005 Superspreading and the
- r43 effect of individual variation on disease emergence. *Nature* **438**, 355-359.
- 744 (doi:10.1038/nature04153).
- 745 [72] Lipsitch, M., Cohen, T., Cooper, B., Robins, J.M., Ma, S., James, L., Gopalakrishna, G.,
- 746 Chew, S.K., Tan, C.C., Samore, M.H., et al. 2003 Transmission Dynamics and Control of Severe
- 747 Acute Respiratory Syndrome. *Science* **300**, 1966-1970. (doi:10.1126/science.1086616).
- 748 [73] Norris, J.R. 1997 Markov Chains (Cambridge Series in Statistical and Probabilistic
- 749 *Mathematics*). Cambridge, Cambridge University Press.

750

### 751 Supplementary Text

752

### 753 Text S1. Probability of a local outbreak

In the Methods section of the main text, we outlined an approach for deriving the probability of a local outbreak

starting from a single infectious host in either the presymptomatic, symptomatic or asymptomatic classes. Here,

we provide more details about that derivation. The probability of a local outbreak not occurring, starting from *i* 

presymptomatic hosts, *j* symptomatic hosts and *k* asymptomatic hosts, is denoted by  $q_{i,j,k}$ . If we consider the

temporal evolution of (i, j, k) to be a Markov process on the state space  $M = \mathbb{Z}_{\geq 0} \times \mathbb{Z}_{\geq 0} \times \mathbb{Z}_{\geq 0}$ , then  $q_{i,j,k}$  is the

hitting probability of the state (0,0,0) starting from the state (*i*, *j*, *k*). The vector of hitting probabilities  $q^* =$ 

760  $\{q_{i,j,k}^* \mid (i,j,k) \in M\}$  is therefore the minimal non-negative (real) solution to the following system of equations:

761 
$$q_{0,0,0} = 1$$

762 
$$q_{i,j,k} = \sum_{(l,m,n) \in M} p_{(i,j,k),(l,m,n)} q_{l,m,n}$$
 for  $(i,j,k) \neq (0,0,0)$ ,

763 where  $p_{(i,j,k),(l,m,n)}$  is the transition probability from state (i, j, k) to state (l, m, n) [73].

Here, minimality means that if  $\hat{q} = \{\hat{q}_{i,j,k} \mid (i,j,k) \in M\}$  is another non-negative real solution, then  $q_{i,j,k}^* \leq M$ 

765  $\hat{q}_{i,i,k}$  for all  $(i, j, k) \in M$ .

766

- From this, equations (3), (4) and (5) in the main text are obtained. These equations may be reduced to the
- 768 following quartic equation for  $q_{0,0,1}$ :

769 
$$\omega_4 q_{0,0,1}{}^4 + \omega_3 q_{0,0,1}{}^3 + \omega_2 q_{0,0,1}{}^2 + \omega_1 q_{0,0,1} + \omega_0 = 0,$$

770 where

$$771 \qquad \omega_{4} = d(a-d)(d-c)\xi;$$

$$772 \qquad \omega_{3} = cd(a-d)(1-d)\xi - bd^{3}(1-c)(1-\xi) + (d-c)[d-a-ad\xi + d^{2}(a-1+b(1-\xi) + \xi)];$$

$$773 \qquad w_{2} = c(1-d)[d-a-ad\xi + d^{2}(a-1+b(1-\xi) + \xi)] + (d-c)[d(d-2a-1) + 2a];$$

$$774 \qquad \omega_{1} = c(1-d)[d(d-2a-1) + 2a] - a(1-d)^{2}(d-c);$$

$$775 \qquad \omega_{0} = -ac(1-d)^{3}.$$

The parameters a, b, c, d and  $\xi$  are as defined in the main text.

777

This yields four solutions for  $q_{0,0,1}$  and four corresponding solutions for each of  $q_{1,0,0}$  and  $q_{0,1,0}$ . One solution is always given by  $q_{1,0,0} = q_{0,1,0} = q_{0,0,1} = 1$ ; the other solutions may be found numerically. As described above, we take the minimal non-negative real solution  $q_{1,0,0} = q_{1,0,0}^*$ ,  $q_{0,1,0} = q_{0,1,0}^*$ ,  $q_{0,0,1} = q_{0,0,1}^*$ , and observe that the probability of a local outbreak occurring starting from *i* presymptomatic hosts, *j* symptomatic hosts and *k* asymptomatic hosts is simply  $1 - q_{i,j,k}$ , giving the result stated in the main text.

783

If required, this result can be confirmed for specific model parameter values via repeated stochastic simulation of the branching process model, starting from *i* presymptomatic hosts, *j* symptomatic hosts and *k* asymptomatic hosts. As described in the main text, in simulations of branching process models, initial cases typically either fade out or go on to cause a local outbreak. There is a natural definition of a local outbreak as a simulation in which a large number of infections occur (see Supplementary Fig S1B). The probability of a local outbreak then corresponds to the proportion of simulations in which large numbers of infections occur.

790

We note here that although this is a natural way to define a local outbreak, alternative definitions exist that may be more appropriate in particular contexts. This is discussed by Thompson *et al.* (reference [41] in the main text), who consider three practically relevant definitions of an outbreak based on different criteria for measuring severity.

795

#### 796 Text S2. Computation of steepest descent contours

797 The steepest descent contours shown in Fig 3A of the main text were computed using a gradient maximisation 798 approach, in which at each point the contour direction was determined by minimising the local outbreak

- probability over a fixed search radius (Fig S2 A,B). Starting from  $\rho_1$ ,  $\rho_2$ , at each step we considered increasing
- 800  $\rho_1$  by an amount  $\Delta \rho_1$  and increasing  $\rho_2$  by an amount  $\Delta \rho_2$  subject to the constraint  $(\Delta \rho_1)^2 + (\Delta \rho_2)^2 = r^2$ ,
- 801 where r is a small pre-specified constant. To achieve this, we scanned over the circular arc  $\Delta \rho_1 =$

802  $r \cos \theta$ ,  $\Delta \rho_2 = r \sin \theta$ , for  $\theta \in [0, \pi/2]$  (Fig S2 A). In practice, this range was discretised into 33 search

directions evenly spaced between 0 and  $\pi/2$ . We then selected the pair of  $\Delta \rho_1$ ,  $\Delta \rho_2$  values for which the local outbreak probability evaluated at  $\rho_1 + \Delta \rho_1$ ,  $\rho_2 + \Delta \rho_2$  was minimised. The process was then repeated beginning from  $\rho_{1_{new}} = \rho_1 + \Delta \rho_1$ ,  $\rho_{2_{new}} = \rho_2 + \Delta \rho_2$  (Fig S2 B). The white line in Fig 3B, which divides the region in which increasing  $\rho_1$  has a greater effect on the local outbreak probability from the region in which increasing  $\rho_2$ has a greater effect on the local outbreak probability, was computed in an analogous way, with the additional restriction that we only considered the search directions  $\theta = 0$  and  $\theta = \pi/2$  (i.e. intensifying only surveillance of nonsymptomatic or symptomatic hosts; see Fig S2 C).

810

811 In Fig 3C, the white line represents the contour of steepest descent under the constraint that the total change in

812 surveillance effort  $(\Delta \rho_1 + \Delta \rho_2 = S)$  is held constant at each step, rather than fixing the search radius  $(\Delta \rho_1)^2 +$ 

813  $(\Delta \rho_2)^2 = r^2$  as in Fig 3A. Therefore, instead of scanning over a circular arc, at each step we scan along the line 814  $\Delta \rho_1 = s$ ,  $\Delta \rho_2 = S - s$ , where *c* varies in the range [0, S] (Fig S2 D). Otherwise, the process is completely

- analogous to that described above.
- 816

#### 817 Text S3. Robustness of results to parameter values used

818 We conducted supplementary analyses to investigate how our results are affected by varying the parameters 819 from their baseline values given in Table 1. We performed sensitivity analyses on the values of  $R_0$ ,  $\xi$ ,  $K_p$ ,  $K_a$ ,  $\gamma$  + 820  $\mu, \epsilon, \lambda, \nu$  and  $\delta$ . For each of these, we present plots analogous to Fig 3D for six different values of the relevant 821 parameter (Figs S3-S12). In each case we considered, our qualitative message was unchanged: whenever the 822 maximum acceptable risk level was below a particular threshold value, the optimal strategy involved 823 surveillance targeting both nonsymptomatic and symptomatic individuals. 824 825 Text S4. Details on computer code 826 All computer code was written in the MATLAB programming environment (version R2019a). 827

- 828
- 829

## 830 Supplementary Figures



832 Fig S1. Illustrating the definition of the term 'local outbreak' with a simple example. A. The total number 833 of individuals ever infected (final epidemic size) in each of 100,000 simulations of a stochastic SIR (Susceptible-834 Infected-Removed) model with basic reproduction number  $R_0 = 2$ , beginning from a single infectious host each time. Within each simulation, each event is either an infection event (with probability  $\frac{R_0S}{R_0S+N}$ ) or a removal event 835 (with probability  $\frac{N}{R_0S+N}$ ), and simulations are run until the pathogen fades out (I hits zero). This provides a 836 837 natural partitioning between simulations that fade out quickly and those that go on to become local outbreaks. In 838 50% of simulations, fewer than 20 infections occurred in total (left hand peak); initial cases did not lead to 839 sustained transmission in the population. In the remaining 50% of simulations (local outbreaks), between 620 840 and 900 individuals were infected in total each time. The probability of a local outbreak is then defined as the 841 proportion of simulations for which the final epidemic size lies within this natural upper range, here equal to 0.5. 842 B. The analogous figure to panel A, but for the branching process version of the SIR model in which depletion of 843 susceptibles is not accounted for (i.e. S = N throughout each simulation). In this model, each event is either an infection event (with probability  $\frac{R_0}{R_0+1}$ ) or a removal event (with probability  $\frac{1}{R_0+1}$ ), and simulations are run until 844 845 either the pathogen fades out (I hits zero) or 1000 infections have occurred. The rightmost bar corresponds to 846 simulations in which 1000 infections occurred. There is again a natural partitioning between simulations that 847 fade out quickly and those that go on to become local outbreaks, with the probability of a local outbreak 848 matching the equivalent value for the stochastic SIR model (panel A).

849



#### 850

851 Fig S2. Computation of the steepest descent contours shown in the main text. A. To compute the steepest 852 descent contours shown in Fig 3A of the main text, we increment  $\rho_1$  and  $\rho_2$  by scanning over a constant search radius  $(\Delta \rho_1)^2 + (\Delta \rho_2)^2 = r^2$  (blue arc), and moving to the point  $(\rho_{1_{new}}, \rho_{2_{new}})$  along that arc at which the local 853 854 outbreak probability is minimised. B. The process shown in A is repeated to generate the complete contour (red 855 dashed line). C. The analogous figure to B, in which the search direction is limited to directly to the right ( $\theta =$ 856 0) or directly upwards ( $\theta = \pi/2$ ). This procedure is used to generate the contour in Fig 3B in the main text. D. 857 The analogous figure to B, in which the total change in surveillance effort  $(\Delta \rho_1 + \Delta \rho_2 = S)$  is held constant at 858 each step, rather than the search radius. This procedure is used to generate the contour in Figs 3C and D in the 859 main text.

860





863 Fig S3. Varying the basic reproduction number  $R_0$  from its baseline value ( $R_0 = 3$ ). Plots are analogous to 864 Fig 3D in the main text, showing strategies for minimising the surveillance effort required to achieve a pre-865 specified risk level (an "acceptable" local outbreak probability). Red dotted lines represent contours along which 866 the probability of a local outbreak is constant, as labelled; red circles indicate the points along these contours at 867 which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates the optimal strategy to follow if 868 the pre-specified risk level is reduced. Apart from  $R_0$  and  $\beta$  (which is changed in each panel to set the value of 869  $R_0$ ), all parameters are held fixed at their baseline values given in Table 1. A.  $R_0 = 1.5$ . B.  $R_0 = 2$ . C.  $R_0 = 2.5$ . 870 D.  $R_0 = 3$  (baseline). E.  $R_0 = 3.5$ . F.  $R_0 = 4$ .



871

872 Fig S4. Varying the proportion of infections from asymptomatic infectors,  $\xi$ , from its baseline value ( $\xi =$ 873 **0.2).** Plots are analogous to Fig 3D in the main text, showing strategies for minimising the surveillance effort 874 required to achieve a pre-specified risk level (an "acceptable" local outbreak probability). Red dotted lines 875 represent contours along which the probability of a local outbreak is constant, as labelled; red circles indicate the 876 points along these contours at which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates 877 the optimal strategy to follow if the pre-specified risk level is reduced. Apart from  $\xi$  and  $\beta$  (which is changed in each panel to set  $R_0 = 3$ ), all parameters are held fixed at their baseline values given in Table 1. A.  $\xi = 0$ . B. 878 879  $\xi = 0.1$ . C.  $\xi = 0.2$  (baseline). D.  $\xi = 0.3$ . E.  $\xi = 0.4$ . F.  $\xi = 0.5$ .



880

881 Fig S5. Varying the proportion of infections arising from presymptomatic hosts in the absence of 882 intensified surveillance ( $K_p$ , given by expression (1) in the main text) from its baseline value ( $K_p$  = 883 **0.489).** In each case, the proportions of infections arising from asymptomatic and symptomatic hosts are 884 adjusted so that they remain in the same ratio as in the baseline case. Plots are analogous to Fig 3D in the main 885 text, showing strategies for minimising the surveillance effort required to achieve a pre-specified risk level (an 886 "acceptable" local outbreak probability). Red dotted lines represent contours along which the probability of a 887 local outbreak is constant, as labelled; red circles indicate the points along these contours at which the total 888 surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates the optimal strategy to follow if the pre-

- specified risk level is reduced. Apart from  $K_p$  and  $K_a$ , as well as  $\alpha$  and  $\eta$  (which are changed in each panel to set the values of  $K_p$  and  $K_a$ ), and  $\beta$  (which is changed in each panel to set  $R_0 = 3$ ), all parameters are held fixed at
- 891 their baseline values given in Table 1. A.  $K_p = 0.2$ . B.  $K_p = 0.3$ . C.  $K_p = 0.4$ . D.  $K_p = 0.5$ . E.  $K_p = 0.6$ . F.
- 892  $K_p = 0.7.$
- 893



Fig S6. Varying the proportion of infections arising from asymptomatic hosts in the absence of intensified surveillance ( $K_a$ , given by expression (2) in the main text) from its baseline value ( $K_a = 0.106$ ). In each

897 case, the proportions of infections arising from presymptomatic and symptomatic hosts are adjusted so that they 898 remain in the same ratio as in the baseline case. Plots are analogous to Fig 3D in the main text, showing 899 strategies for minimising the surveillance effort required to achieve a pre-specified risk level (an "acceptable" 900 local outbreak probability). Red dotted lines represent contours along which the probability of a local outbreak is 901 constant, as labelled; red circles indicate the points along these contours at which the total surveillance effort 902  $\rho_1 + \rho_2$  is minimised. The white line indicates the optimal strategy to follow if the pre-specified risk level is 903 reduced. Apart from  $K_p$  and  $K_a$ , as well as  $\alpha$  and  $\eta$  (which are changed in each panel to set the values of  $K_p$  and 904  $K_a$ ), and  $\beta$  (which is changed in each panel to set  $R_0 = 3$ ), all parameters are held fixed at their baseline values 905 given in Table 1. A.  $K_a = 0.01$ . B.  $K_a = 0.05$ . C.  $K_a = 0.1$ . D.  $K_a = 0.15$ . E.  $K_a = 0.2$ . F.  $K_a = 0.25$ .



907

908 Fig S7. Varying the expected time period to isolation conditional on isolation occurring during the 909 symptomatic period,  $1/(\gamma + \mu)$ , from its baseline value  $(1/(\gamma + \mu) = 4.6$  days). This is achieved by 910 varying the parameter  $\gamma$ , whilst holding the recovery rate of symptomatic individuals  $\mu$  equal to its baseline 911 value ( $\mu = 1/8 \text{ days}^{-1}$ ). Plots are analogous to Fig 3D in the main text, showing strategies for minimising the 912 surveillance effort required to achieve a pre-specified risk level (an "acceptable" local outbreak probability). Red 913 dotted lines represent contours along which the probability of a local outbreak is constant, as labelled; red circles 914 indicate the points along these contours at which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white 915 line indicates the optimal strategy to follow if the pre-specified risk level is reduced. Apart from  $\gamma$  and  $\beta$  (which

- 916 is changed in each panel to set  $R_0 = 3$ ), all parameters are held fixed at their baseline values given in Table 1. A.
- 917  $1/(\gamma + \mu) = 2$  days. B.  $1/(\gamma + \mu) = 3$  days. C.  $1/(\gamma + \mu) = 4$  days. D.  $1/(\gamma + \mu) = 5$  days. E.  $1/(\gamma + \mu) = 6$
- 918 days. F.  $1/(\gamma + \mu) = 7$  days.
- 919



920

921 Fig S8. Varying  $\epsilon$ , the relative isolation rate of nonsymptomatic individuals without intensified

922 surveillance (compared to symptomatic individuals), from its baseline value ( $\epsilon = 0.1$ ). Plots are analogous 923 to Fig 3D in the main text, showing strategies for minimising the surveillance effort required to achieve a pre-924 specified risk level (an "acceptable" local outbreak probability). Red dotted lines represent contours along which

925 the probability of a local outbreak is constant, as labelled; red circles indicate the points along these contours at 926 which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates the optimal strategy to follow if 927 the pre-specified risk level is reduced. Apart from  $\epsilon$  and  $\beta$  (which is changed in each panel to set  $R_0 = 3$ ), all 928 parameters are held fixed at their baseline values given in Table 1. A.  $\epsilon = 0.01$ . B.  $\epsilon = 0.02$ . C.  $\epsilon = 0.05$ . D. 929  $\epsilon = 0.1$  (baseline). E.  $\epsilon = 0.2$ . F.  $\epsilon = 0.3$ .

930





933 Plots are analogous to Fig 3D in the main text, showing strategies for minimising the surveillance effort required

medRxiv preprint doi: https://doi.org/10.1101/2020.11.06.20226969; this version posted April 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

to achieve a pre-specified risk level (an "acceptable" local outbreak probability). Red dotted lines represent contours along which the probability of a local outbreak is constant, as labelled; red circles indicate the points along these contours at which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates the optimal strategy to follow if the pre-specified risk level is reduced. Apart from  $\lambda$  and  $\beta$  (which is changed in each panel to set  $R_0 = 3$ ), all parameters are held fixed at their baseline values given in Table 1. A.  $1/\lambda = 0.5$ days. B.  $1/\lambda = 1$  day. C.  $1/\lambda = 2$  days (baseline). D.  $1/\lambda = 4$  days. E.  $1/\lambda = 6$  days. F.  $1/\lambda = 8$  days.





942 Fig S10. Varying the duration of the symptomatic period,  $1/\mu$ , from its baseline value ( $1/\mu = 8$  days). The 943 parameter  $\gamma$  is varied simultaneously such that  $1/(\gamma + \mu)$ , the expected time period to isolation conditional on 944 isolation occurring during the symptomatic period, remains at its baseline value  $(1/(\gamma + \mu) = 4.6 \text{ days})$ . Plots 945 are analogous to Fig 3D in the main text, showing strategies for minimising the surveillance effort required to 946 achieve a pre-specified risk level (an "acceptable" local outbreak probability). Red dotted lines represent 947 contours along which the probability of a local outbreak is constant, as labelled; red circles indicate the points 948 along these contours at which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates the 949 optimal strategy to follow if the pre-specified risk level is reduced. Apart from  $\mu$  and  $\gamma$ , and  $\beta$  (which is changed 950 in each panel to set  $R_0 = 3$ ), all parameters are held fixed at their baseline values given in Table 1. A.  $1/\mu =$ 951 5 days. B.  $1/\mu = 6$  days. C.  $1/\mu = 7$  days. D.  $1/\mu = 8$  days (baseline). E.  $1/\mu = 9$  days. F.  $1/\mu = 10$  days. 952



953

954 Fig S11. Varying  $1/\nu$ , the duration of the asymptomatic period, from its baseline value ( $1/\nu = 10$  days). 955 Plots are analogous to Fig 3D in the main text, showing strategies for minimising the surveillance effort required 956 to achieve a pre-specified risk level (an "acceptable" local outbreak probability). Red dotted lines represent 957 contours along which the probability of a local outbreak is constant, as labelled; red circles indicate the points 958 along these contours at which the total surveillance effort  $\rho_1 + \rho_2$  is minimised. The white line indicates the 959 optimal strategy to follow if the pre-specified risk level is reduced. Apart from  $\nu$  and  $\beta$  (which is changed in 960 each panel to set  $R_0 = 3$ ), all parameters are held fixed at their baseline values given in Table 1. A.  $1/\nu = 7$ 961 days. B.  $1/\nu = 8$  days. C.  $1/\nu = 9$  days. D.  $1/\nu = 10$  days (baseline). E.  $1/\nu = 11$  days. F.  $1/\nu = 12$  days.





963 Fig S12. Varying the upper bound on the fractional reduction in the time to isolation (if no other event 964 occurs),  $\delta$ , from its baseline value ( $\delta = 0.8$ ). Plots are analogous to Fig 3D in the main text, showing 965 strategies for minimising the surveillance effort required to achieve a pre-specified risk level (an "acceptable" 966 local outbreak probability). Red dotted lines represent contours along which the probability of a local outbreak is 967 constant, as labelled; red circles indicate the points along these contours at which the total surveillance effort 968  $\rho_1 + \rho_2$  is minimised. The white line indicates the optimal strategy to follow if the pre-specified risk level is 969 reduced. Apart from  $\delta$ , all parameters are held fixed at their baseline values given in Table 1. A.  $\delta = 0.5$ . B.  $\delta =$ 970 0.6. C.  $\delta = 0.7$ . D.  $\delta = 0.8$  (baseline). E.  $\delta = 0.9$ . F.  $\delta = 0.95$